CAI · Caris Life Sciences, Inc.
$21.80
-0.38 (-1.71%)
At close · Aug 14
Market Cap
$6.16B
Shares
282.60M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Utilization
17.9%
$17,900,000 used of $100,000,000
| Program Announced | Authorized | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2026-08-05 | $100,000,000 | $82,100,000 | 2026-08-05 | — | 8-K , filed 2026-08-05 |
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source | ||
|---|---|---|---|---|
| 2026-06-30 YTD | $21,361,000 | 10-Q, filed 2026-08-05 | ||
| 2025-12-31 | $113,000 | 10-K, filed 2026-03-03 | ||
Key facts
CIK
2019410
CUSIP
142152107
13F (30d)
232 filings
231 filers
Visit website
Investor relations